Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Antonio Toesca is active.

Publication


Featured researches published by Antonio Toesca.


Critical Reviews in Oncology Hematology | 2013

Breast phyllodes tumor: A review of literature and a single center retrospective series analysis

Gianluca Spitaleri; Antonio Toesca; Edoardo Botteri; Luca Bottiglieri; Nicole Rotmensz; Sabrina Boselli; Claudia Sangalli; Chiara Catania; Francesca Toffalorio; Cristina Noberasco; Angelo Delmonte; Alberto Luini; Paolo Veronesi; Marco Colleoni; Giuseppe Viale; S. Zurrida; Aron Goldhirsch; Umberto Veronesi; Tommaso De Pas

PURPOSE Complete surgical resection is the standard treatment for localized breast phyllodes tumors. Post-surgical treatments are still a matter of debate. We carried out an overview of the literature to investigate the clinical outcome of patients with phyllodes tumor. A retrospective analysis of mono-institutional series has been included as well. METHODS We reviewed all the retrospective series reported from 1951 until April 2012. We analyzed cases treated at our institution from 1999 to 2010. RESULTS Eighty-three articles (5530 patients; 1956 malignant tumors) were reviewed. Local recurrences were independent of histology. Distant recurrences were more frequent in the malignant tumors (22%). A total of 172 phyllodes tumors were included in the retrospective analysis. DISCUSSION Prognosis of phyllodes tumors is excellent. There are no convincing data to recommend any adjuvant treatment after surgery. Molecular characterization may well provide new clues to permit identification of active treatments for the rare poor prognosis cases.


Ejso | 2013

The indocyanine green method is equivalent to the 99mTc-labeled radiotracer method for identifying the sentinel node in breast cancer: A concordance and validation study

Bettina Ballardini; L. Santoro; Claudia Sangalli; Oreste Gentilini; Giuseppe Renne; Germana Lissidini; G Pagani; Antonio Toesca; C. Blundo; A. del Castillo; N. Peradze; Pietro Caldarella; Paolo Veronesi

AIMS The aim of this study was to assess concordance between the indocyanine green (ICG) method and (99m)Tc-radiotracer method to identify the sentinel node (SN) in breast cancer. Evidence supports the feasibility and efficacy of the ICG to identify the SN, however this method has not been prospectively compared with the gold-standard radiotracer method in terms of SN detection rate. METHODS Between June 2011 and January 2013, 134 women with clinically node-negative early breast cancer received subdermal/peritumoral injection of (99m)Tc-labeled tracer for lymphoscintigraphy, followed by intraoperative injection of ICG for fluorescence detection of SNs using an exciting light source combined with a camera. In all patients, SNs were first identified by the fluorescence method (ICG-positive) and removed. A gamma ray-detecting probe was then used to determine whether ICG-positive SNs were hot ((99m)Tc-positive) and to identify and remove any (99m)Tc-positive (ICG-negative) SNs remaining in the axilla. The study was powered to perform an equivalence analysis. RESULTS The 134 patients provided 246 SNs, detected by one or both methods. 1, 2 and 3 SNs, respectively, were detected, removed and examined in 70 (52.2%), 39 (29.1%) and 17 (12.7%) patients; 4-10 SNs were detected and examined in the remaining 8 patients. The two methods were concordant for 230/246 (93.5%) SNs and discordant for 16 (6.5%) SNs. The ICG method detected 99.6% of all SNs. CONCLUSIONS Fluorescent lymphangiography with ICG allows easy identification of axillary SNs, at a frequency not inferior to that of radiotracer, and can be used alone to reliably identify SNs.


Annals of Oncology | 2009

Unavoidable mastectomy for ipsilateral breast tumour recurrence after conservative surgery: patient outcome

Edoardo Botteri; Nicole Rotmensz; Claudia Sangalli; Antonio Toesca; Nickolas Peradze; H. R. De Oliveira Filho; Andrea Sagona; Mattia Intra; Paolo Veronesi; Viviana Galimberti; A. Luini; Umberto Veronesi; Oreste Gentilini

BACKGROUND In the case of ipsilateral breast tumour recurrence (IBTR) after breast-conserving surgery (BCS), a second conservative surgical approach maybe considered in some motivated patients whereas in others mastectomy is unavoidable. PATIENTS AND METHODS From 1997 to 2004, 282 patients presented at the European Institute of Oncology with an operable invasive IBTR after BCS. One hundred and sixty-one (57%) underwent a second conservative surgery, whereas 121 patients (43%) were given a mastectomy and represent the study population. We investigated the prognosis and determined predictive factors of outcome. RESULTS Median time from primary breast cancer to IBTR was 41 months (range 5-213). Recurrences were T2-T4 and/or multifocal in 83 cases (68.6%). With a median follow-up of 5 years after mastectomy, 5-year overall survival (OS) and disease-free survival (DFS) were 73.3% [95% confidence interval (CI) 65.0% to 81.6%] and 50.4% (95% CI 40.9% to 59.8%), respectively. At the multivariate analysis, early onset of IBTR, presence of vascular invasion and Ki67 >or=20 of the recurrent tumour were found to significantly affect both DFS and OS. CONCLUSIONS In women who need mastectomy for IBTR, early onset of the relapse, high proliferation index and presence of vascular invasion represent the worst prognostic factors.


Annals of Surgery | 2017

Robotic Nipple-sparing Mastectomy and Immediate Breast Reconstruction With Implant: First Report of Surgical Technique

Antonio Toesca; Nickolas Peradze; Viviana Galimberti; Andrea Manconi; Mattia Intra; Oreste Gentilini; Daniele Sances; Debora Negri; Giulia Veronesi; Mario Rietjens; Stefano Zurrida; Alberto Luini; Umberto Veronesi; Paolo Veronesi

To the Editor:Technical innovations have made it feasible to conduct endoscopic nipple-sparing mastectomy (NSM), which has been reportedly well tolerated and associated with greater patient satisfaction.1 However, the endoscopic technique (ET) has not had a wide diffusion and many centers have aband


Clinical Breast Cancer | 2012

Sarcoma of the Breast: Outcome and Reconstructive Options

Antonio Toesca; Gianluca Spitaleri; Tommaso De Pas; Edoardo Botteri; Oreste Gentilini; Luca Bottiglieri; Nicole Rotmentsz; Claudia Sangalli; Emilia Marrazzo; Enrico Cassano; Paolo Veronesi; Mario Rietjens; Alberto Luini

INTRODUCTION Surgery is the mainstay of treatment for all breast sarcomas. The role of adjuvant chemotherapy and radiation therapy has not been clearly defined. The aim of this single-center retrospective study was to analyze prognostic factors, outcome, and recent advances. MATERIALS AND METHODS Data from 203 patients with all breast sarcomas treated in a single center were collected from 1996 to 2010. Phyllodes tumors and metastatic disease at presentation were excluded from the population. Thirty-six women and 1 man were included in the analysis. Local recurrence, metastatic disease, survival, and reconstructive outcome were evaluated. RESULTS Thirty-four patients out of 37 (91.9%) had an angiosarcoma and 3 had a stromal sarcoma (8.1%). Twenty-one patients (56.8%) had previously undergone breast radiation therapy for breast carcinoma or lymphoma. Twenty-six patients (70.3%) underwent mastectomy, 14 of whom (53.8%) with breast reconstruction. Thirty-six patients (97.3%) had free margins, 1 (2.7%) had a microscopically focally involved margin after surgery. Five patients received adjuvant chemotherapy and 6 received adjuvant radiation therapy. Median follow-up was 58 months (range, 4-146 months). Twelve sarcoma-related deaths were observed with a 5-year cumulative incidence of 43.4%. Twenty-four sarcoma-related events were observed with a 5-year cumulative incidence of 70.8%. The same figure was 49.7% in patients affected by primary sarcoma and 85.7% in patients with secondary sarcoma (P = .06). CONCLUSION Secondary sarcomas were associated with a higher risk of events. Patients undergoing breast conservative surgery or reconstruction after mastectomy did not show a worse prognosis compared with patients undergoing mastectomy.


The Breast | 2010

Breast-conserving surgery in 201 very young patients (<35 years)

Oreste Gentilini; Edoardo Botteri; Nicole Rotmensz; Antonio Toesca; Helio De Oliveira; Claudia Sangalli; Marco Colleoni; Mattia Intra; Viviana Galimberti; Paolo Veronesi; Alberto Luini; Umberto Veronesi

INTRODUCTION Surgical treatment of breast cancer in very young patients (<35 years) is still a matter of debate, since age is a predictive factor of local recurrence after breast conservation. PATIENTS AND METHODS We retrospectively evaluated outcome and prognostic factors of 201 consecutive patients treated with breast conservation followed by whole breast irradiation between 1997 and 2004 with special attention paid to local control. The average follow up was 72 months (range 13-133 months). RESULTS The mean age was 32 years (Range 20-34). Invasive ductal carcinoma was found in 175 (87.1%) patients. Two (1%) patients had invasive lobular carcinoma. One-hundred and eighteen patients (58.7%) had tumors of 2 cm or smaller. Sentinel lymph node biopsy was performed in 105 (52.2%) patients. One-hundred and ten (54.7%) patients had node-negative disease, 68 (33.8%) patients had 1-3 positive nodes and 23 (11.4%) +4 positive nodes. Eighteen patients (9.0%) developed a local recurrence, 25 (12.5%) developed distant metastases and 23 patients (11.4%) died during follow up. The 5- and 10-year cumulative incidence of local events were 8.2% and 12,3% respectively. The univariate analysis did not identify any variables affecting local disease-free survival. CONCLUSIONS Breast conservation in very young patients achieves an acceptable local control rate. No prognostic factors were associated with local events.


Breast Care | 2011

Sentinel Lymph Node Biopsy in Early Breast Cancer: The Experience of the European Institute of Oncology in Special Clinical Scenarios

Antonio Toesca; Alberto Luini; Paolo Veronesi; Mattia Intra; Oreste Gentilini

Background: While axillary nodal status is still one of the most important prognostic factors in breast cancer, sentinel lymph node biopsy (SLNB) has evolved as a main procedure to strongly reduce postsurgical morbidity improving early and long-term quality of life. Material and Methods: Between 1996 and 2010, we performed 18,884 SLNBs for breast cancer, successfully confirming the validity of this technique and its positive impact on patients’ quality of life, even though decision-making processes for adjuvant treatment strongly depend on biological features. Results: This paper summarizes published data mainly collected in our institute considering special clinical scenarios such as ductal intraepithelial neoplasia, intramammary sentinel nodes, multicentric breast cancer, prior breast surgery, previous breast aesthetic surgery, second axillary SLNB, pregnant patients, primary chemotherapy, and male patients. Conclusions: In general, we believe that SLNB represents the standard procedure for axillary staging in virtually all clinical situations, even in those which were previously considered a contraindication for this procedure. At the moment, the only contraindication to SLNB is the presence of documented axillary metastases.


Gynecological Surgery | 2014

Locoregional treatment of breast cancer during pregnancy

Antonio Toesca; Oreste Gentilini; Fedro Peccatori; Hatem A. Azim; Frédéric Amant

The management of patients with breast cancer during pregnancy is very demanding and it should be better performed in highly qualified and experienced centers. Referral to institutes and physicians trained in this special clinical scenario allows reducing the risk of both overtreating and undertreating the patients. Moreover, patients can receive appropriate information regarding safety of treatments without old-fashioned taboo. The purpose of the current paper is to discuss the main issues concerning surgical management and in general locoregional treatment of patients diagnosed with breast cancer and treated during gestation, focusing on those women who chose to continue their pregnancy. We cover the issues regarding type of breast surgery, radiation therapy, immediate reconstruction during mastectomy, and management of the axilla.


The Breast | 2014

Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence

Antonio Toesca; Edoardo Botteri; Matteo Lazzeroni; Jose Vila; Aikaterini Manika; Bettina Ballardini; Francesca Bettarini; Aliana Guerrieri-Gonzaga; Bernardo Bonanni; Nicole Rotmensz; Giuseppe Viale; Paolo Veronesi; Alberto Luini; Umberto Veronesi; Oreste Gentilini

RATIONAL We retrospectively analyzed 232 patients affected by well differentiated ductal intraepithelial neoplasia (DIN1c or DCIS G1) treated with conservative surgery without adjuvant radiotherapy. RESULTS 25 invasive and 18 non-invasive local recurrences were observed (median follow-up 80 months; 5-year cumulative incidence: 12.2%). Seven of the 15 young patients (<40 y) developed local recurrence (2 in situ, 5 invasive). Age <50 (HR 1.89, 95% C.I. 1.01-3.45), multifocality (HR 3.21, 95% C.I. 1.46-7.06), Ki-67 > 7% (HR 2.33, 95% C.I. 1.20-4.55) and surgical margins <10 mm (HR 2.00, 95% C.I. 1.06-3.76) were significantly associated with an increased risk of local recurrence. CONCLUSIONS Young age, multifocality and small margins appeared as clear risk factors of local recurrence in DIN1c (DCIS G1) population. The presence of multiple poor prognostic features warrant a thorough discussion regarding local treatment.


International Journal of Surgery | 2015

Breast cancer subtypes can be determinant in the decision making process to avoid surgical axillary staging: A retrospective cohort study

Antonio Marrazzo; Giovanni Boscaino; Emilia Marrazzo; Pietra Taormina; Antonio Toesca

INTRODUCTION The need for performing axillary lymph-node dissection in early breast cancer when the sentinel lymph node (SLN) is positive has been questioned in recent years. The purpose of this study was to identify a low-risk subgroup of early breast cancer patients in whom surgical axillary staging could be avoided, and to assess the probability of having a positive lymph-node (LN). METHODS We evaluated the cohort of 612 consecutive women affected by early breast cancer. We considered age, tumor size, histological grade, vascular invasion, lymphatic invasion and cancer subtype (Luminal A, Luminal B HER-2+, Luminal B HER-2-, HER-2+, and Triple Negative) as variables for univariate and multivariate analyses to assess probability of there being a positive SLN o nonsentinel lymph node (NSLN). Chi-square, Fishers Exact test and Students t tests were used to investigate the relationship between variables; whereas logit models were used to estimate and quantify the strength of the relationship among some covariates and SLN or the number of metastases. RESULTS A significant positive effect of vascular invasion and lymphatic invasion (odds ratios are 4 and 6), and a negative effect of TN (odds ratios is 10) were noted. With respect to positive NSLN, size alone has a significant (positive) effect on tumor presence, but focusing on the number of metastases, also age has a (negative) significant effect. CONCLUSION This work shows correlation between subtypes and the probability of having positive SLN. Patients not expressing vascular invasion, lymphatic invasion and, moreover, a triple-negative tumor subtype may be good candidates for breast conservative surgery without axillary surgical staging.

Collaboration


Dive into the Antonio Toesca's collaboration.

Top Co-Authors

Avatar

Paolo Veronesi

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Viviana Galimberti

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Oreste Gentilini

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Alberto Luini

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Giuseppe Viale

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Nicole Rotmensz

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Bernardo Bonanni

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Edoardo Botteri

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Mattia Intra

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Nickolas Peradze

European Institute of Oncology

View shared research outputs
Researchain Logo
Decentralizing Knowledge